Einloggen

Thematische Bibliographien / Methotrexate Toxicology / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Methotrexate Toxicology.

Zeitschriftenartikel zum Thema „Methotrexate Toxicology“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 1. Februar 2022

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Methotrexate Toxicology" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Slørdal, L., R. Jaeger, J. Kjaeve und J. Aarbakke. „Pharmacokinetics of 7-Hydroxy-methotrexate and Methotrexate in the Rat“. Pharmacology & Toxicology 63, Nr. 2 (August 1988): 81–84. http://dx.doi.org/10.1111/j.1600-0773.1988.tb00915.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

UNDP/UNFPA/WHO/World Bank Special P. „Methotrexate for the termination of early pregnancy: a toxicology review“. Reproductive Health Matters 5, Nr. 9 (Januar 1997): 162–67. http://dx.doi.org/10.1016/s0968-8080(97)90020-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Armagan, A., E. Uzar, E. Uz, HR Yilmaz, S. Kutluhan, HR Koyuncuoglu, S. Soyupek, H. Cam und TA Serel. „Caffeic acid phenethyl ester modulates methotrexate-induced oxidative stress in testes of rat“. Human & Experimental Toxicology 27, Nr. 7 (Juli 2008): 547–52. http://dx.doi.org/10.1177/0960327108092293.

Der volle Inhalt der Quelle

Annotation:

The aim of this study was to investigate the possible protective role of caffeic acid phenethyl ester on testicular toxicity of methotrexate in rats. Nineteen male rats were divided into three groups as follows: group I, control; group II, methotrexate-treated; group III, methotrexate + caffeic acid phenethyl ester-treated. In the second day of experiment, a single dose of methotrexate was intraperitoneally administered to groups II and III, although a daily single dose of caffeic acid phenethyl ester was intraperitoneally administered to group III for 7 days. At the end of the experiment, the testes of the animals were removed and weighed. In the tissue, the level of lipid peroxidation as malondialdehyde and activities of superoxide dismutase were higher in the methotrexate group than in the control group. Lipid peroxidation levels and superoxide dismutase activities were decreased in caffeic acid phenethyl ester + methotrexate group compared with methotrexate group. The activities of catalase in the methotrexate group decreased insignificantly although its activities were significantly increased by caffeic acid phenethyl ester administration. The activity of glutathione peroxidase did not change in the groups. There was significant difference in body weight between control and methotrexate-induced groups. In conclusion, the administration of methotrexate causes elevation of oxidative stress although treatment with caffeic acid phenethyl ester has protective effects on the oxidative stress in testes.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Bardin, Philip G., David J. Fraenkel und Richard W. Beasley. „Methotrexate in Asthma“. Drug Safety 9, Nr. 3 (September 1993): 151–55. http://dx.doi.org/10.2165/00002018-199309030-00002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Gökçe, Ahmet, Suleyman Oktar, Ahmet Koc und Zafer Yonden. „Protective effects of thymoquinone against methotrexate-induced testicular injury“. Human & Experimental Toxicology 30, Nr. 8 (02.09.2010): 897–903. http://dx.doi.org/10.1177/0960327110382564.

Der volle Inhalt der Quelle

Annotation:

Thymoquinone is the major active component derived from Nigella sativa. Methotrexate is a folic acid antagonist widely used in clinic. Aim of this study was to investigate the possible protective role of thymoquinone on testicular toxicity of methotrexate. Experiments were performed on male C57BL/6 mice (6 weeks old, 20 ± 2 g). The animals were divided into four groups with six mice in each group. Equivalent volumes of saline were injected intraperitoneally (i.p.) in the control group. In the thymoquinone group, mice received thymoquinone i.p. with a dose of 10 mg/kg/day for 4 days. Mice in the methotrexate group received single dose of methotrexate i.p., with a dose of 20 mg/kg. Finally, in the methotrexate plus thymoquinone group, in the first and the following 3 days after methotrexate administration, thymoquinone was injected with a dose of 10 mg/kg/day, i.p. At the end of the experiment, the left testis was quickly removed and divided into two parts for histological examination and biochemical analysis. Methotrexate alone increased total antioxidant capacity and myeloperoxidase activity compared to the controls. Thymoquinone treatment decreased total antioxidant capacity and prevented the increase in the myeloperoxidase activity. Light microscopy showed in mice that receiving methotrexate resulted in interstitial space dilatation, edema, severe disruption of the seminiferous epithelium and reduced diameter of the seminiferous tubules. Administration of thymoquinone reversed histological changes of methotrexate significantly. We suggest that thymoquinone use may decrease the destructive effects of methotrexate on testicular tissue of patients using this agent.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Roy(Pal), Madhumita, Sharmila Sengupta, Rita Ghosh, Nitao P. Bhattacharyya, Subrata K. Dey und Sukhendu B. Bhattacharjee. „Characterisation of methotrexate-resistant clones“. Mutation Research/Environmental Mutagenesis and Related Subjects 291, Nr. 1 (Februar 1993): 43–51. http://dx.doi.org/10.1016/0165-1161(93)90016-s.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Angelova, E., M. Krsnik-Rasol, M. Biruš und D. Papeš. „Methotrexate effects on plant cells“. Mutation Research/Environmental Mutagenesis and Related Subjects 271, Nr. 2 (1992): 148. http://dx.doi.org/10.1016/0165-1161(92)91162-k.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Raveendran, R., W. Heybroek, M. Caulfield, M. Lawson, S. M. L. Abrams, P. F. M. Wrigley, M. Slevin und P. Turner. „Indomethacin and Protein Binding of Methotrexate“. Human & Experimental Toxicology 11, Nr. 4 (Juli 1992): 291–93. http://dx.doi.org/10.1177/096032719201100411.

Der volle Inhalt der Quelle

Annotation:

Indomethacin, a non-steroidal anti-inflammatory drug is known to increase the efficacy and toxicity of methotrexate, the widely used anti-cancer drug in man. The mechanism for this interaction has not been clearly established. However, since these drugs bind with albumin, a possible displacement of methotrexate by indomethacin from albumin might explain this interaction. To investigate the possible interaction an in-vitro protein-binding displacement study was carried out in 17 normal volunteers and in two groups of eight cancer patients. One group of patients had active disease and the other was in complete clinical remission. Serum samples were obtained and protein levels estimated. The protein binding of methotrexate was measured alone and with indomethacin using equilibrium dialysis. Statistical analysis of results suggested that the binding of methotrexate is not influenced by indomethacin, confirming that methotrexate is not displaced by indomethacin.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

LoVecchio, Frank, Kenneth D. Katz, David J. Watts und Ian O. Wood. „Four-year experience with methotrexate exposures“. Journal of Medical Toxicology 4, Nr. 3 (September 2008): 149–50. http://dx.doi.org/10.1007/bf03161192.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Stockley, Ivan H. „Methotrexate—NSAID interactions“. Drug Intelligence & Clinical Pharmacy 21, Nr. 6 (Juni 1987): 546. http://dx.doi.org/10.1177/106002808702100617.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Drafi, Frantisek, Katarina Bauerova, Viera Kuncirova, Silvester Ponist, Danica Mihalova, Tatiana Fedorova, Juraj Harmatha und Radomir Nosal. „Pharmacological influence on processes of adjuvant arthritis: effect of the combination of an antioxidant active substance with methotrexate“. Interdisciplinary Toxicology 5, Nr. 2 (09.11.2012): 84–91. http://dx.doi.org/10.2478/v10102-012-0015-4.

Der volle Inhalt der Quelle

Annotation:

Abstract Oxygen metabolism has an important role in the pathogenesis of rheumatoid arthritis. A certain correlation was observed between oxidative stress, arthritis and the immune system. Reactive oxygen species produced in the course of cellular oxidative phosphorylation and by activated phagocytic cells during oxidative burst, exceed the physiological buffering capacity and result in oxidative stress. The excessive production of ROS can damage protein, lipids, nucleic acids, and matrix components. Patients with rheumatoid arthritis have an altered antioxidant defense capacity barrier. In the present study the effect of substances with antioxidative properties, i.e. pinosylvin and carnosine, was determined in monotherapy for the treatment of adjuvant arthritis (AA). Moreover carnosine was evaluated in combination therapy with methotrexate. Rats with AA were administered first pinosylvin (30 mg/kg body mass daily per os), second carnosine (150 mg/kg body mass daily per os) in monotherapy for a period of 28 days. Further, rats with AA were administered methotrexate (0.3 mg/kg body mass 2-times weekly per os), and a combination of methotrexate+carnosine, with the carnosine dose being the same as in the previous experiment. Parameters, i.e. changes in hind paw volume and arthritic score were determined in rats as indicators of destructive arthritis-associated clinical changes. Plasmatic levels of TBARS and lag time of Fe2+- induced lipid peroxidation (tau-FeLP) in plasma and brain were specified as markers of oxidation. Plasmatic level of CRP and activity of γ-glutamyltransferase (GGT) in spleen and joint were used as inflammation markers. In comparison to pinosylvin, administration of carnosine monotherapy led to a significant decrease in the majority of the parameters studied. In the combination treatment with methotrexate+carnosine most parameters monitored were improved more remarkably than by methotrexate alone. Carnosine can increase the disease-modifying effect of methotrexate treatment in rat AA.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Giannini, Edward H., und James T. Cassidy. „Methotrexate in Juvenile Rheumatoid Arthritis“. Drug Safety 9, Nr. 5 (November 1993): 325–39. http://dx.doi.org/10.2165/00002018-199309050-00002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Bebarta, Vikhyat S., Matthew D. Hensley und Douglas J. Borys. „Acute Methotrexate Ingestions in Adults: A Report of Serious Clinical Effects and Treatments“. Journal of Toxicology 2014 (2014): 1–5. http://dx.doi.org/10.1155/2014/214574.

Der volle Inhalt der Quelle

Annotation:

Objective.Limited reported data have reports effects after acute ingestion of methotrexate. Treatment recommendations do not differentiate between exposure routes. Our objective was to determine the frequency of significant toxicity effects and use of therapy after methotrexate ingestion in adults.Methods.We performed a retrospective study on adult cases reported to 6 poison centers over 6 years (2000–2005) which exceed 180,000 exposures/year. Variables collected included demographics, dosages ingested, coingestions, clinical effects, and therapies with outcomes.Results.Sixty-three patients examined over the 6-year period met inclusion criteria. No patient in the series received dialysis or died. The mean dose ingested for all patients was 24 mg (range 2.5–100 mg) and the mean dose for suicidal ingestions was 47.5 mg (12.5–100 mg). The most common clinical effects were abdominal pain, oral irritation, throat irritation, nausea, dizziness, and headache. Nine patients received folinic acid and 3 patients received sodium bicarbonate. No patient developed renal failure, bone marrow suppression, seizure, or coma. No patient died or received dialysis.Conclusion.In our series of patients from 6 poison centers over six years, 63 cases of acute adult methotrexate ingestions were reported. Methotrexate toxicity from ingestion in adults was uncommon and rarely toxic.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

CURD, CHERYL D., JOSEPH E. MANNO und JOHN J. STEWART. „Effects of Methotrexate on Intestinal Transit in Rats“. Toxicological Sciences 5, Nr. 5 (1985): 991–96. http://dx.doi.org/10.1093/toxsci/5.5.991.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Wolfgang, William J. „Exploring Protection from Methotrexate-Induced Teratogenicity in Flies“. Toxicological Sciences 99, Nr. 2 (Oktober 2007): 363–65. http://dx.doi.org/10.1093/toxsci/kfm198.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

CURD, C. „Effects of methotrexate on intestinal transit in rats“. Fundamental and Applied Toxicology 5, Nr. 5 (Oktober 1985): 991–96. http://dx.doi.org/10.1016/0272-0590(85)90181-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Remington, Helen St C., und Clifford C. Bailey. „Methotrexate Blood Level Monitoring“. Drug Intelligence & Clinical Pharmacy 19, Nr. 5 (Mai 1985): 372–73. http://dx.doi.org/10.1177/106002808501900508.

Der volle Inhalt der Quelle

Annotation:

Methotrexate toxicity can be avoided following high-dose therapy if certain management procedures are adhered to. These include careful fluid balance management and therapeutic drug level monitoring. A case is reported of an episode of methotrexate toxicity resulting from a fluid balance problem.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Severin, María J., Mara S. Trebucobich, Patricia Buszniez, Anabel Brandoni und Adriana M. Torres. „The urinary excretion of an organic anion transporter as an early biomarker of methotrexate-induced kidney injury“. Toxicology Research 5, Nr. 2 (2016): 530–38. http://dx.doi.org/10.1039/c5tx00436e.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Hendel, J., H. Poulsen, B. Nyfors und A. Nyfors. „Changes in Liver Histology during Methotrexate Therapy of Psoriasis Correlated to the Concentration of Methotrexate and Folate in Erythrocytes“. Acta Pharmacologica et Toxicologica 56, Nr. 4 (13.03.2009): 321–26. http://dx.doi.org/10.1111/j.1600-0773.1985.tb01297.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Verberne, Eline A., Emma de Haan, J. Peter van Tintelen, Dick Lindhout und Mieke M. van Haelst. „Fetal methotrexate syndrome: A systematic review of case reports“. Reproductive Toxicology 87 (August 2019): 125–39. http://dx.doi.org/10.1016/j.reprotox.2019.05.066.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Affleck, Joslynn G., und Virginia K. Walker. „Transgenic Rescue of Methotrexate-Induced Teratogenicity in Drosophila melanogaster“. Toxicological Sciences 99, Nr. 2 (22.05.2007): 522–31. http://dx.doi.org/10.1093/toxsci/kfm123.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Chaudhary, Sushma, Manjul Pratap Singh, Chandana Venkateaswara Rao und Ajay Kumar Singh Rawat. „A Novel Natural Polymers Based Nanoparticles Gel Formulation for the Treatment of Rheumatoid Arthritis: Optimization and In-vivo Evaluation“. Drug Delivery Letters 11, Nr. 2 (28.06.2021): 164–78. http://dx.doi.org/10.2174/2210303111666210219152401.

Der volle Inhalt der Quelle

Annotation:

Background: In 1988, the US Food and Drug Administration permitted low dose methotrexate for the treatment of rheumatoid arthritis that would change the progression of the disease. Methotrexate is a folic acid antagonist and its systemic use causes numerous side effects; including hepatic toxicity. It would be preferable to deliver methotrexate by the topical route to reduce side-effects along with ease of administration and reduced dosing frequency. So, nanoparticle gel is a hopeful approach to treat rheumatoid arthritis. Objective: The study aims to develop a nanoparticles gel containing novel natural polymer-based methotrexate nanoparticles and evaluate its therapeutic potential on Complete Freund’s Adjuvant– Induced Arthritis rat model and compare it to methotrexate and dexamethasone gel. Materials and Methods: The five batches of methotrexate nanoparticles gel were prepared viz. F1W2, F2W2, F3W2, F4W2 and methotrexate gel for the topical application by using different concentrations of Carbopol 934 base and characterized for their evaluation parameters: homogeneity, grittiness, pH, spread-ability, viscosity determination, and drug content studies. The arthritic potential of methotrexate-nanoparticles gel was evaluated by Complete Freund’s Adjuvant–Induced Arthritis rats model based on percent inhibition oedema and arthritic score. Result and Discussion: Methotrexate nanoparticles gel significantly reduced the percentage inhibition of oedema compared to methotrexate and dexamethasone gel. The therapeutic activity of nanoparticles gel was found to be F3W2 ≥ F2W2 ≥ F1W2 ≥ F4W2 ≥ MTX gel. So, the optimized nanoparticle gel formulation F3W2 can be effective in the treatment of rheumatoid arthritis. Conclusion: The developed novel nanoparticles gel formulation can be a promising alternative to existing methotrexate and dexamethasone gel.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Del Campo, Miguel, Kenjiro Kosaki, F. C. Bennett und Kenneth L. Jones. „Developmental delay in fetal aminopterin/methotrexate syndrome“. Teratology 60, Nr. 1 (Juli 1999): 10–12. http://dx.doi.org/10.1002/(sici)1096-9926(199907)60:1<10::aid-tera5>3.0.co;2-h.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Donnenfeld, Alan E., Anne Pastuszak, Jane Salkoff Noah, Betsy Schick, Nancy C. Rose und Gideon Koren. „Methotrexate exposure prior to and during pregnancy“. Teratology 49, Nr. 2 (Februar 1994): 79–81. http://dx.doi.org/10.1002/tera.1420490202.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Schuurman, Henk-Jan, Harold T. Smith und Emanuele Cozzi. „Tolerability of cyclosphosphamide and methotrexate induction immunosuppression in nonhuman primates“. Toxicology 213, Nr. 1-2 (September 2005): 1–12. http://dx.doi.org/10.1016/j.tox.2005.03.017.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Ezhilarasan, Devaraj. „Hepatotoxic potentials of methotrexate: Understanding the possible toxicological molecular mechanisms“. Toxicology 458 (Juni 2021): 152840. http://dx.doi.org/10.1016/j.tox.2021.152840.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Vericat, J. E. Megías, S. Valero García, M. Amat Díaz, E. López Briz, M. N. Vila Clérigues und J. L. Poveda Andrés. „Stability of two methotrexate oral formulations“. European Journal of Hospital Pharmacy 19, Nr. 2 (12.03.2012): 150.1–150. http://dx.doi.org/10.1136/ejhpharm-2012-000074.173.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Benitez, B., E. Capilla, L. Gonzalez, M. P. Garcia de Miguel, C. Rueda, G. Casado, H. Varela, T. Roldan, M. Bravo und A. Herrero. „Carboxypeptidase rescue after high-dose methotrexate“. European Journal of Hospital Pharmacy 19, Nr. 2 (12.03.2012): 157.1–157. http://dx.doi.org/10.1136/ejhpharm-2012-000074.189.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Bowen, Donnell, Terry J. Robbins und Robert M. White. „Interaction of 5?-deoxy-5-fluorouridine and methotrexate“. Archives of Toxicology 63, Nr. 5 (September 1989): 401–5. http://dx.doi.org/10.1007/bf00303130.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

González‐Barón, M., M. P. Iniesta, M. I. Sanchez Reus und B. Ribas. „Anticarcinogenic methotrexate induces metallothionein synthesis†“. Toxicological & Environmental Chemistry 13, Nr. 3-4 (Januar 1987): 161–70. http://dx.doi.org/10.1080/02772248709357179.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Scanlon, Kevin J., Mohammed Kashani-Sabet, Arlene R. Cashmore, Michele Pallai, Barbara A. Moroson und Maria Saketos. „The role of methionine in methotrexate-sensitive and methotrexate-resistant mouse leukemia L1210 cells“. Cancer Chemotherapy and Pharmacology 19, Nr. 1 (Februar 1987): 25–29. http://dx.doi.org/10.1007/bf00296250.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Bremnes, R. M., E. Smeland, N. E. Huseby, T. J. Eide und J. Aarbakke. „Acute Hepatotoxicity after High-Dose Methotrexate Administration to Rats“. Pharmacology & Toxicology 69, Nr. 2 (August 1991): 132–39. http://dx.doi.org/10.1111/j.1600-0773.1991.tb01286.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Finkelstein, Y. „Emergency Treatment of Life-Threatening Intrathecal Methotrexate Overdose“. NeuroToxicology 25, Nr. 3 (März 2004): 407–10. http://dx.doi.org/10.1016/j.neuro.2003.10.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Wheeler, Marsha, Patrick O'Meara und Michelle Stanford. „Fetal methotrexate and misoprostol exposure: The past revisited“. Teratology 66, Nr. 2 (22.07.2002): 73–76. http://dx.doi.org/10.1002/tera.10052.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Bawle, E. V., J. V. Conard und L. Weiss. „Adult and two children with fetal methotrexate syndrome“. Teratology 57, Nr. 2 (Februar 1998): 51–55. http://dx.doi.org/10.1002/(sici)1096-9926(199802)57:2<51::aid-tera2>3.0.co;2-9.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Finkelstein, Yoram, Shoshana Zevin, Bianca Raikhlin-Eisenkraft und Yedidia Bentur. „Intrathecal methotrexate neurotoxicity: clinical correlates and antidotal treatment“. Environmental Toxicology and Pharmacology 19, Nr. 3 (Mai 2005): 721–25. http://dx.doi.org/10.1016/j.etap.2004.12.031.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Yawata, Ayako, Saki Kimura, Misato Matsushita, Takehiro Mochizuki, Toshiyuki Chikuma, Hiroshi Hojo und Yasumitsu Ogra. „Cell-specific Synergic Effect of Cimicifugoside on Cytotoxicity of Methotrexate“. JOURNAL OF HEALTH SCIENCE 57, Nr. 4 (2011): 350–55. http://dx.doi.org/10.1248/jhs.57.350.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Martín, María Cecilia, Pablo Barbero, Boris Groisman, Miguel Ángel Aguirre und Gideon Koren. „Methotrexate embryopathy after exposure to low weekly doses in early pregnancy“. Reproductive Toxicology 43 (Januar 2014): 26–29. http://dx.doi.org/10.1016/j.reprotox.2013.10.005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Fuksa, Leos, Eva Brcakova, Gabriela Kolouchova, Petra Hirsova, Milos Hroch, Jolana Cermanova, Frantisek Staud und Stanislav Micuda. „Dexamethasone reduces methotrexate biliary elimination and potentiates its hepatotoxicity in rats“. Toxicology 267, Nr. 1-3 (Januar 2010): 165–71. http://dx.doi.org/10.1016/j.tox.2009.11.010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Wang, Xiuwei, Jianhua Wang, Tao Guan, Qian Xiang, Mingsheng Wang, Zhen Guan, Guannan Li et al. „Role of methotrexate exposure in apoptosis and proliferation during early neurulation“. Journal of Applied Toxicology 34, Nr. 8 (09.07.2013): 862–69. http://dx.doi.org/10.1002/jat.2901.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Zhang, Chun-yu, Yuan-xi Feng, Yang Yu, Wen-jing Sun, Jing Bai, Feng Chen und Song-bin Fu. „The Molecular Mechanism of Resistance to Methotrexate in Mouse Methotrexate-Resistant Cells by Cancer Drug Resistance and Metabolism SuperArray“. Basic Clinical Pharmacology Toxicology 99, Nr. 2 (August 2006): 141–45. http://dx.doi.org/10.1111/j.1742-7843.2006.pto_470.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Yuksel, Yasemin, Ramazan Yuksel, Murat Yagmurca, Hacer Haltas, Husamettin Erdamar, Muhsin Toktas und Osman Ozcan. „Effects of quercetin on methotrexate-induced nephrotoxicity in rats“. Human & Experimental Toxicology 36, Nr. 1 (11.07.2016): 51–61. http://dx.doi.org/10.1177/0960327116637414.

Der volle Inhalt der Quelle

Annotation:

Objective: This experimental study was conducted to elucidate the possible protective/therapeutic effects of quercetin against methotrexate (Mtx)-induced kidney toxicity with biochemical and histopathological studies. Methods: Twenty-four adult male rats were randomly divided into four groups, as follows: control group (saline intraperitoneally (i.p.), 9 days), Mtx group (20 mg/kg i.p., single dose), Mtx + quercetin group (50 mg/kg quercetin was orally administered 2 days before and 6 days after Mtx administration) and only quercetin group (50 mg/kg oral, 9 days). Structural changes were evaluated by hematoxylin–eosin and periodic acid–Schiff stainings. Apoptotic changes were investigated by terminal deoxynucleotidyl transferase dUTP nick end labeling assay and caspase-3 antibody. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels were measured in tissue and plasma samples. Results: Mtx compared with the control group, there was significant increase in nephrotoxic tissue damage findings, in addition to apoptotic index (APOI) and caspase-3 expression ( p < 0.05). Mtx + quercetin group revealed significantly lower histopathological damage and APOI and caspase-3 expression decreased when compared to Mtx group. MDA levels were increased in Mtx group compared to others, and by the use of quercetin, this increase was significantly reduced. SOD levels were higher in Mtx group than others. This increase was evaluated as a relative increase arising from oxidative damage caused by Mtx. Conclusion: As a result, Mtx administration may involve oxidative stress by causing structural and functional damage in kidney tissue in rats. Quercetin reduced the Mtx-induced oxidative stress through its antioxidant properties and so quercetin may be promising to alleviate Mtx-induced renal toxicity.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Nolte, H., und P. Stahl Skov. „Inhibition of basophil histamine release by methotrexate“. Agents and Actions 23, Nr. 3-4 (Mai 1988): 173–76. http://dx.doi.org/10.1007/bf02142532.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Venkatesan Kotteeswaran, Vidhyutha Srivathsan, Mahima Bhandari, Juanit Thomas E und Trishita Bhattacharya. „Characterization of Methotrexate Loaded Fucoidan/Chitosan Nanoparticles“. International Journal of Research in Pharmaceutical Sciences 11, SPL4 (21.12.2020): 2644–54. http://dx.doi.org/10.26452/ijrps.v11ispl4.4534.

Der volle Inhalt der Quelle

Annotation:

Methotrexate is one of the most popular and safe anti-inflammatory drugs which is an antifolate-type antimetabolite and is used as an anticancer drug. In this study, oppositely charged chitosan and fucoidan have been non-covalently bonded using their electrostatic interactions with the methotrexate drug loaded into these nanoparticles. Fucoidan is obtained from marine algae which are composed of l-fucose and sulfate groups in various types of brown seaweeds; whereas chitosan is a naturally occurring biopolymer obtained through the N-deacetylation of chitin. Depending on the fucoidan / chitosan (F / C) weight ratio, three distinct nanoparticles (1F / 1C; 3F / 1C; 5F / 1C) are synthesized and characterized. Nanoparticles were prepared using cross linkers EDC and NHS at a constant pH to reduce the conjugate size. The prepared conjugates were characterized for their size and zeta potential using DLS analysis and the functional groups were analysed using FTIR. DLS results proclaimed that there was size reduction in particle size with cross linker and without the drug methotrexate. The 5:1 F/C nanoparticles was seen to be 441.5 nm, the difference being considerable larger in the 5:1 formulation. Hence for further analysis 5:1 F/C nanoparticles were preferred. Maximum entrapment efficiency was observed in 5:1 F/C nanoparticle with and without cross linkers. To understand the structural morphology of nanoparticles electromagnetic magnification like SEM and TEM were taken in account.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Weitman, Steven D., Gregory J. Kato, Jerry L. Barbosa und Barton A. Kamen. „Low-dose methotrexate therapy for hepatoblastoma“. Cancer Chemotherapy and Pharmacology 28, Nr. 3 (1991): 233–34. http://dx.doi.org/10.1007/bf00685519.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Çetiner, Mustafa, Göksel Şener, A. Özer Şehirli, Emel Ekşioğlu-Demiralp, Feriha Ercan, Serap Şirvancı, Nursal Gedik, Sertaç Akpulat, Tülay Tecimer und Berrak Ç. Yeğen. „Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death“. Toxicology and Applied Pharmacology 209, Nr. 1 (November 2005): 39–50. http://dx.doi.org/10.1016/j.taap.2005.03.009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Ibsen, Hans Henning W. „Electroencephalographic Examination in Seven Patients Treated with Methotrexate for Psoriasis“. Acta Pharmacologica et Toxicologica 58, Nr. 4 (13.03.2009): 303–4. http://dx.doi.org/10.1111/j.1600-0773.1986.tb00113.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Mouridsen, H. T., E. Jacobsen und O. Faber. „The Pharmacokinetics of Cyclophosphamide in Man Following Treatment with Methotrexate“. Acta Pharmacologica et Toxicologica 38, Nr. 5 (13.03.2009): 508–12. http://dx.doi.org/10.1111/j.1600-0773.1976.tb03146.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

David, N. Bailey, Joseph J. Coffee und R. Briggs John. „Percutaneous absorption of methotrexate as its sodium salt in vivo“. Journal of Toxicology: Cutaneous and Ocular Toxicology 6, Nr. 1 (Januar 1987): 9–12. http://dx.doi.org/10.3109/15569528709052159.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Koçak, Aslıhan Yonca, Oğuzhan Koçak, Figen Aslan und Mustafa Tektaş. „Methotrexate toxicity presenting as cutaneous ulcerations on psoriatic plaques“. Cutaneous and Ocular Toxicology 32, Nr. 4 (28.03.2013): 333–35. http://dx.doi.org/10.3109/15569527.2013.779278.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!